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Abstract
Background: Management of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia remains a challenge.
The emergence of MRSA strains with reduced vancomycin susceptibility complicates treatment.
Methods: A prospective cohort study (2005-2007) of patients with MRSA bacteremia treated with vancomycin was
performed at an academic hospital. Vancomycin minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) were determined for stored MRSA isolates. Cox regression analysis was performed
to predict 28-day all-cause mortality.
Results: One hundred sixty-three patients with MRSA bacteremia were evaluated. One hundred twelve patients
(68.7%) had bacteremia due to MRSA with a vancomycin MIC ≥ 2 ug/mL. Among strains with a vancomycin MIC ≥
2 ug/mL, 10 isolates (8.9%) were vancomycin-intermediate S. aureus (VISA). Thirty-five patients (21.5%) died within
28 days after the diagnosis of MRSA bacteremia. Higher vancomycin MIC was not associated with mortality in this
cohort [adjusted hazard ratio (aHR), 1.57; 95% confidence interval (CI), 0.73-3.37]. Vancomycin tolerance was
observed in 4.3% (7/162) of isolates and was not associated with mortality (crude HR, 0.62; 95% CI, 0.08-4.50).
Factors independently associated with mortality included higher age (aHR, 1.03; 95% CI 1.00-1.05), cirrhosis (aHR,
3.01; 95% CI, 1.24-7.30), and intensive care unit admission within 48 hours after the diagnosis of bacteremia (aHR,
5.99; 95% CI, 2.86-12.58).
Conclusions: Among patients with MRSA bacteremia treated with vancomycin, reduced vancomycin susceptibility
and vancomycin tolerance were not associated with mortality after adjusting for patient factors. Patient factors
including severity of illness and underlying co-morbidities were associated with the mortality.
Background
Methicillin-resistant Staphylococcus aureus (MRSA) bac-
teremia is a common infection. In a recent epidemiolo-
gical study of nine US communities, the pooled mean
incidence of MRSA bacteremia was 2.24 per 10, 000
population per year [1]. MRSA bacteremia is increas-
ingly seen in the general community [2]. MRSA bactere-
mia is often complicated by medical device involvement,
metastatic infection, recurrence, and mortality. MRSA
bacteremia is also associated with a worse outcome
compared to bacteremia caused by methicillin-suscepti-
ble S. aureus [3-5]. Management of MRSA bacteremia is
a challenge since clinical cure may not be achieved in
selected cases, despite the appropriate antimicrobial
therapy [6]. Vancomycin remains the mainstay treat-
ment for MRSA bacteremia [7]. However, reduced van-
comycin susceptibility may be associated with worse
clinical outcomes (i.e., mortality or septic shock) among
patients with MRSA bacteremia [8-10]. This observation
led in part to the lowering of the breakpoint for vanco-
mycin susceptibility to ≤ 2 μg/mL by the Clinical and
Laboratory Standards Institute (CLSI) in 2006 [11].
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association between vancomycin MIC and clinical out-
come [12-14]. Some of this variability may be explained
by other phenotypic characteristics such as vancomycin
minimal bactericidal concentration (MBC) or vancomy-
cin tolerance [15,16]. The purpose of our study is to
determine the impact of phenotypic characteristics on
mortality of MRSA bacteremia using comprehensive
data (2005-2007) from large prospective cohort at US
tertiary hospital.
Methods
A prospective cohort study of patients with MRSA bac-
teremia was conducted between July 2005 and July 2007
at Barnes-Jewish Hospital, a 1252-bed, academic, tertiary
care centre in St. Louis, Missouri. Diagnosis of MRSA
bacteremia was defined as ≥ 1 blood culture positive for
MRSA. Patients who did not receive vancomycin as
initial therapy or were less than 18 years old at the time
of diagnosis of MRSA bacteremia were excluded. In
order to analyze incident cases of invasive MRSA infec-
tions, patient who had a history of MRSA bacteremia in
the previous three months, or a history of MRSA endo-
carditis in the twelve months prior to initial positive
blood culture at our hospital during the study period
were also excluded. Isolates from MRSA bacteremia
were individually labeled and separately stored at - 40°
C for microbiological analysis.
Microbiological analysis
Minimum inhibitory concentrations (MIC) were deter-
mined by microbroth dilution method, using the SIE-
MENS (West Sacramento, CA) MicroScan
® -P o sM I C
Panel Type 26 as a testing platform. Briefly, MicroScan
®
panels were inoculated according to manufacturer’s
instruction using colonies of Staphylococcus aureus
grown overnight on Remel tryptic soy agar blood agar
plates (Lenexa, KS). Panels were incubated at 35°C in
room air. Panels were run in full manual mode, and all
microbroth dilution panels were manually read by a sin-
gle investigator (C.D.C.) and MIC data was recorded for
each isolate at 24 hours. The vancomycin doubling dilu-
tion range for this assay was from 0.25 to 16 mg/L.
Enterococcus faecalis ATCC 29212 and Staphylococcus
aureus ATCC 29213 strains were used for quality con-
trol using the reference ranges provided in the package
insert.
The MBC values were obtained using the method of
Sader, et al. [17] The minimum bactericidal concentra-
tions (MBC) for vancomycin were defined as 99.9% kill-
ing of the initial inocula after 24 hours of incubation.
Following 24 hours of incubation, colony counts were
conducted from the MIC well and every well thereafter
demonstrating no bacterial growth. After thoroughly re-
suspending each well, two aliquots of 20 μl were plated
to TSA blood agar plates for isolation and subsequent
colony counts. An average of the two aliquots was mul-
tiplied by the dilution factor (1:5). The MBC was estab-
lished as the first well with less than 99.9% of the initial
inoculum. Repeat testing was conducted on those iso-
lates with MBCs > 16 μg/mL to confirm the result. Van-
comycin- intermediate S. aureus was defined as strains
having a vancomycin MIC of 4 or 8 μg/mL by micro-
broth dilution testing [11]. Vancomycin tolerance was
defined by either an MBC: MIC ratio ≥ 32 or an MBC:
MIC ratio of 16 associated with a resistant-level vanco-
mycin MBC (≥ 32 μg/mL) [16-18].
Definitions and data collection
Patients were identified by daily review of microbiology
reports. Demographic characteristics and clinical data
were prospectively obtained from the medical record. A
written informed consent from the patients was waived
for this observational study. We tracked all-cause mor-
tality for 28 days after the first blood culture positive for
MRSA by reviewing both medical records and the Social
Security Death Index [19]. If the patient did not die on
initial hospital stay, then any patients readmitted > 28
days after the initial diagnosis of MRSA bacteremia
were considered to be alive at 28 days. If there were no
readmission data > 28 days after diagnosis of MRSA
bacteremia available, Social Security Death Index was
used to determine if patients died. Metastatic infection
was defined by microbiological or radiographic evidence
of remote site of infection consistent with hematogen-
ous spread [20]. Healthcare-associated, hospital-onset
bacteremia was defined by a positive blood culture
obtained from patients who were hospitalized > 48
hours [21]. Healthcare-associated, community onset of
bacteremia was defined as a positive blood culture ≤ 48
hours after hospitalization with the following criteria;
presence of an invasive device, history of MRSA infec-
tion or colonization, surgery, hospitalization, dialysis, or
residence in a long-term care facility in the 12 months
preceding the culture [21]. Community-associated bac-
teremia was defined by a positive blood culture ≤ 48
hours without meeting the criteria of healthcare asso-
ciated community-onset bacteremia [21].
Statistical analyses
Vancomycin MIC was dichotomized (MIC of ≤ 1 μg/mL
and MIC ≥ 2 μg/mL). Comparison between categorical
variables was done using Chi-square or Fisher’s exact
test. Continuous variables were compared using the
Mann-Whitney test. Two-tailed Spearman’sr h ow a s
used to calculate correlation coefficients between vanco-
mycin MIC and MBC. All tests for significance were 2-
tailed, with P values < 0.05 considered significant.
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dict 28-day all-cause mortality. Potential risk factors for
28-day all-cause mortality were first assessed by bivari-
ate analysis. A Cox proportional hazards model was
developed in forward stepwise fashion to predict mortal-
ity. The variable of vancomycin MIC (either ≤ 1 μg/mL
or ≥ 2 μg/mL) was forced into the final model since this
was the independent variable of interest. Variables with
P < 0.10 in bivariate analysis were considered for inclu-
sion in the models. The assumption of proportional
hazards was confirmed by log-log survival plots for inde-
pendent variables in the final model. A first-order inter-
action term of initial vancomycin trough level (< or ≥
15 μg/dL) and vancomycin MIC was created to deter-
mine if a lower vancomycin trough and higher vanco-
mycin MIC independently increased mortality. Other
variables were retained in the final model if P < 0.05.
All analyses were performed using SPSS version 17.0
(SPSS Inc, Chicago, IL). The Washington University
Human Research Protection (institutional review board)
approved this project.
Results
One hundred-sixty three patients met study criteria dur-
ing the 25-month study period and were included in the
analysis. The vancomycin MIC was ≤ 1 μg/mL for 51
(31.3%) isolates, and ≥ 2 μg/mL for 112 (68.7%) isolates
(MIC50 =2μg/mL). Ten isolates (6.1%) had a vancomy-
cin MIC of 4 μg/mL. Only one isolate had a vancomycin
MIC of 0.5 μg/mL. There were no isolates with a vanco-
mycin MIC > 4 μg/mL in this cohort.
The vancomycin MBC for all isolates ranged from 1 to
≥ 32 μg/mL (MBC50 and MBC90 were 2 μg/mL and 8
μg/mL, respectively, Table 1). Seven (4.3%) isolates met
t h ec r i t e r i af o rv a n c o m y c i nt o l e r a n c e ,w h i l et h eM B C :
MIC ratio to determine vancomycin tolerance for one
isolate could not be determined (The strain with a van-
comycin MIC of 4 μg/mL and MBC ≥ 32 μg/mL).
Overall, vancomycin MIC was highly correlated with
vancomycin MBC (r = 0.734, p < 0.001). A comparison
of study patients by vancomycin MIC is shown in Table
2. There were no significant differences in patient char-
acteristics between patients infected with MRSA isolates
having low versus high vancomycin MICs.
The 28-day all-cause mortality rate for the cohort was
21.5%. Median length of time from the time of first
positive blood culture to death was 13 days (range; 1-28
days). Predictors of 28-day mortality of MRSA bactere-
m i aa r es h o w ni nT a b l e3 .I n c r e a s e da g e ,c h r o n i cr e n a l
insufficiency without dialysis,c i r r h o s i s ,v a s c u l a rg r a f t ,
central venous catheter at the time of bacteremia, ICU
admission within 48 hours at the time of first positive
blood culture, and vancomycin MIC > 2 μg/mL were
considered for inclusion in the multivariate model. In
the multivariate model, factors independently associated
with mortality were increased age [adjusted hazard ratio
(aHR), 1.03 per year; 95% confidence interval (CI), 1.00-
1.05], cirrhosis (aHR, 3.01; 95% CI, 1.24-7.30), and ICU
a d m i s s i o nw i t h i n4 8h o u r so fd i a g n o s i s( a H R ,5 . 9 9 ;9 5 %
CI, 2.86-12.58). Lower initial vancomycin trough level (i.
e., < 15 μg/dL) was not associated with 28-day mortality
(n = 151, crude HR, 0.77; 95% CI, 0.36-1.63). MRSA
phenotype characteristics, both vancomycin susceptibil-
ity ≥ 2 μg/mL (adjusted HR, 1.57; 95% CI, 0.73-3.37)
and vancomycin tolerance (n = 162, crude HR, 0.62;
95% CI, 0.08-4.50) were not associated with 28-day
mortality.
Discussion
In contrast to previous studies, [8-10] we did not
observe an association between 28-day all-cause mortal-
ity and increased vancomycin MIC (≥ 2 μg/ml) or van-
comycin tolerance among patients with MRSA
bacteremia, after adjusting for underlying patient factors.
In this prospective cohort, the incidence of MRSA
bacteremia due to strains with a vancomycin MIC of 2
μg/ml and VISA bacteremia (i.e., MIC ranging 4-8 μg/
ml) was 62.6% and 6.1%, respectively. According to 2005
Surveillance Network data from a large sample of US
laboratories, S. aureus isolates with reduced susceptibil-
ity to vancomycin was rare; the percentage of over 240,
000 isolates with vancomycin MIC of 2 μg/ml and van-
comycin MIC ≥ 4 was 16.2% and 0.2%, respectively [11].
Musta et al. showed in their cohort, the percentage of
MRSA blood culture isolates with a vancomycin MIC of
2 μg/ml (including 1.5 μg/ml) and > 2 μg/ml was 82.8%
and 2.7%, respectively [13]. The reason for our cohort
having a higher prevalence of strains with reduced van-
comycin susceptibility and VISA was not completely
clear. The current prevalence of VISA in the US is
unknown. Since our cohort included the data from
2007, this might be indicative of an overall increase in
Table 1 Vancomycin Minimum Inhibitory Concentration
and Minimum Bactericidal Concentration for 163 Isolates
of Methicillin-Resistant S. aureus Bacteremia
Vancomycin MBC (ug/mL)
Vancomycin
MIC
(ug/mL)
No. of isolates
(%)
(n = 163)
1248 1 6 ≥32
< 1 1 (0.6) —— 1 —— —— —— ——
1 50 (30.6) 37 12 —— —— 1 ——
2 102 (62.6) —— 75 14 6 —— 7
a
4 10 (6.1) —— —— 7111
b
MIC, minimum inhibitory concentration; MBC, minimum bactericidal
concentration.
a. Seven isolates were met the criteria for vancomycin tolerance.
b. MBC: MIC ratio for one isolate was undetermined.
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Page 3 of 8Table 2 Comparison of 163 Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia, by Vancomycin
Minimum Inhibitory Concentration
Variable MIC (ug/mL)
≤ 1
(n = 51)
≥ 2
(n = 112)
p
Age, years, median (range) 54 (26-95) 59 (23-92) .115
Female gender 23 (45.1) 60 (53.6) .316
White race 22 (43.1) 51 (45.5) .775
Congestive heart failure 10 (19.6) 25 (22.3) .696
Coronary artery disease 11 (21.6) 26 (23.2) .817
Chronic obstructive pulmonary diseases 15 (29.4) 22 (19.6) .167
Renal function
Normal 36 (70.6) 81 (72.3) Ref.
c
Chronic renal insufficiency without dialysis 4 (7.8) 10 (8.9) .866
Chronic renal insufficiency with dialysis 11 (21.6) 21 (18.8) .697
Malignancy 10 (19.6) 25 (22.3) .696
HIV infection 4 (7.8) 3 (2.7) .206
Chronic skin disease 5 (9.8) 8 (7.1) .547
Peripheral vascular diseases 4 (7.8) 7 (6.3) .741
Diabetes mellitus 27 (52.9) 34 (30.4) .006
Systemic corticosteroid use last 28 days 9 (17.6) 15 (13.4) .477
Cirrhosis 4 (7.8) 10 (8.9) 1.00
History of intravenous drug use 4 (7.8) 11 (9.8) .778
History of smoking 29 (56.9) 67 (58.9) .865
Any transplant 2 (3.9) 8 (7.1) .726
Surgery during hospitalization 10 (19.6) 13 (11.6) .174
Prosthetic joint 4 (7.8) 11 (9.8) .778
Vascular graft 9 (17.6) 14 (12.5) .381
Cardiac device 4 (7.8) 6 (5.4) .506
ICU admission within 48 hours after the first positive blood culture 19 (37.3) 40 (35.7) .849
Central venous catheterization at the time of the first (+) blood culture 37 (72.5) 77 (68.8) .624
Onset
Community-associated 4 (7.8) 8 (7.1) Ref.
c
Healthcare-associated community onset 32 (62.7) 66 (58.9) .962
Healthcare-associated hospital onset 15 (29.4) 38 (33.9) .730
Site of MRSA bacteremia
Primary bacteremia 25 (49.0) 45 (40.2) Ref
c
Catheter related bloodstream infection 12 (23.5) 25 (22.3) .344
Skin infection 8 (15.7) 17 (15.2) .508
Postoperative surgical site infection 2 (3.9) 12 (10.7) .552
Other 4 (7.8) 13 (11.6) .520
Any metastatic infection at the time of diagnosis 6 (11.8) 17 (15.2) .562
Outcome
Recurrent MRSA infection (n = 161)
a, b 10/51 (19.6) 16/110 (14.5) .417
Death at 28 days after diagnosis of bacteremia 9 (17.6) 26 (23.2) .422
HIV, human immunodeficiency virus; ICU, intensive care unit; MRSA, methicillin-resistant S. aureus.
Ref, reference; MIC, minimum inhibitory concentration.
a. See methods for definition.
b. Two patients were excluded from analysis since they died within 48 hours of diagnosis.
c. P value determined using univariate logistic regression.
Percentage of each column with variable is shown in parentheses, unless otherwise stated.
Honda et al. BMC Infectious Diseases 2011, 11:335
http://www.biomedcentral.com/1471-2334/11/335
Page 4 of 8vancomycin MIC among MRSA. However, a large sam-
ple of isolates must be tested to confirm this.
In previous studies, Soriano et al, demonstrated pro-
gressively higher vancomycin MICs (ranging between 1,
1.5, and 2 μg/ml) were associated with increased 30-day
mortality when vancomycin was used to treat MRSA
bacteremia [10]. A paradoxical relationship (i.e.,
increased vancomycin MIC was correlated with better
clinical outcome) was also observed in one study [14].
The discordant finding of these various studies has gen-
erated several hypotheses, including a potential differ-
ence in strain virulence due to geographic location.
Although a trend towards increased mortality was
observed among our few patients infected with MRSA
Table 3 Predictors of 28-day All-Cause Mortality after Diagnosis of Methicillin-Resistant Staphylococcus aureus
Bacteremia for 163 Patients
Variable Death
(n = 35)
Alive
(n = 128)
Crude HR
(95% CI)
Adjusted HR
(95% CI)
Age, years, median (range) 64 (33-92) 56 (23-95) 1.03 (1.00-1.05) 1.03 (1.00-1.05)
Female gender 16 (45.7) 67 (52.3) 0.83 (0.43-1.61)
White race 20 (57.1) 70 (54.7) 1.05 (0.54-2.05)
Congestive heart failure 9 (25.7) 26 (20.3) 1.33 (0.62-2.84)
Coronary artery disease 8 (22.9) 29 (22.7) 0.99 (0.45-2.19)
Chronic obstructive pulmonary diseases 10 (28.6) 27 (21.1) 1.43 (0.69-2.97)
Renal function
Normal 25 (71.4) 92 (71.9) Reference
CRI without dialysis 7 (20.0) 7 (5.5) 2.67 (1.15-6.17)
CRI with dialysis 3 (8.6) 29 (22.7) 0.42 (0.13-1.37)
Malignancy 8 (22.9) 27 (21.1) 1.08 (0.49-2.37)
HIV infection 1 (2.9) 6 (4.7) 0.58 (0.08-4.26)
Chronic skin disease 2 (5.7) 11 (8.6) 0.69 (0.17-2.87)
Peripheral vascular diseases 2 (5.7) 9 (7.0) 0.81 (0.19-3.37)
Diabetes mellitus 10 (28.6) 51 (39.8) 0.64 (0.31-1.32)
Systemic corticosteroid use last 28 days 8 (22.9) 16 (12.5) 2.01 (0.91-4.42)
Cirrhosis 6 (17.1) 8 (6.3) 2.50 (1.04-6.02) 3.01 (1.24-7.30)
History of intravenous drug use 2 (5.7) 13 (10.2) 0.57 (0.14-2.37)
History of smoking 22 (62.9) 73 (57.0) 1.27 (0.64-2.52)
Alcohol use 11 (31.4) 39 (30.5) 1.06 (0.52-2.15)
Any transplant 2 (5.7) 8 (6.3) 0.89 (0.22-3.73)
Surgery during hospitalization 4 (11.4) 19 (14.8) 0.78 (0.28-2.21)
Prosthetic joint 0 15 (11.7) 0.04 (0-5.06)
Vascular graft 1 (2.9) 22 (17.2) 0.16 (0.02-1.16)
Cardiac device 3 (8.6) 7 (5.5) 1.40 (0.43-4.56)
ICU admission within 48 hours after the first positive blood culture 25 (71.4) 34 (26.6) 5.56 (2.67-11.60) 5.99 (2.86-12.58)
Central venous catheterization at the time of the first positive blood culture 29 (82.9) 85 (66.4) 2.25 (0.93-5.42)
Onset
Community-associated 3 (8.6) 9 (7.0) Reference
Healthcare-associated community onset 21 (60.0) 77 (60.2) 0.76 (0.23-2.55)
Healthcare-associated hospital onset 11 (31.4) 42 (32.8) 0.75 (0.21-2.67)
Any metastatic infection at the time of diagnosis 6 (17.1) 17 (13.3) 1.27 (0.53-3.05)
Vancomycin tolerance (n = 162)
a, b 1/35 (2.9) 6/127 (4.7) 0.62 (0.08-4.50)
Vancomycin initial trough < 15 mg/L
(n = 151)
c
14/27 (51.9) 73/124 (58.9) 0.77 (0.36-1.63)
Vancomycin MIC ≥ 2 ug/mL 26 (74.3) 86 (67.2) 1.36 (0.64-2.89) 1.57 (0.73-3.37)
CRI, chronic renal insufficiency; HIV, human immunodeficiency virus; ICU, intensive care unit;
MRSA, methicillin-resistant S. aureus; HR, hazard ratio; MIC, minimum inhibitory concentration.
Variables considered but not retained in the final model were renal function (chronic renal failure without dialysis), vascular graft, central venous catheterization
at the time of diagnosis, and vancomycin MIC ≥2 ug/mL.
a. See methods for definition.
b. One patient was excluded since MBC: MIC ratio was undetermined.
c. Twelve patients did not have an initial vancomycin trough level. [unknown reason (n = 7) or died before initial trough was obtained (n = 5)]
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statistically significant (data not shown).
Among the 151 patients in which an initial vancomy-
cin trough was obtained, a lower vancomycin trough
level was not associated with increased mortality in our
cohort, which has been reported by others [22]. Treat-
ment failure of MRSA bacteremia using vancomycin
raises questions about the ideal serum vancomycin con-
centration for treatment of S. aureus bacteremia. Based
on limited animal studies and Monte Carlo simulation
studies, the targeted therapeutic range of vancomycin
[area under the concentration-versus-time curve (AUC):
MIC of ≥ 400] is not achievable with conventional van-
comycin dosing if the MIC is ≥ 2 μg/ml in patients with
normal renal function [23,24]. This led to a recommen-
dation not to use vancomycin for a AUC:MIC ratio ≥
400. However, there is no definitive human clinical data
to support this recommendation [24]. Moreover,
nephrotoxicity is a concern when a higher dose of van-
comycin is administered [25]. We created a model with
an interaction variable for both higher vancomycin (≥ 2
μg/ml) and lower initial vancomycin trough level (< 15
mg/L), however this interaction variable was not asso-
ciated with increased mortality (data not shown). Our
finding supports the hypothesis that vancomycin MIC of
2 μg/ml may not always predict worse outcome in
patients with MRSA bacteremia.
The effect of vancomycin MBC and vancomycin toler-
ance on patient outcome have rarely been examined in
clinical practice. Vancomycin tolerance may be asso-
ciated with reduced efficacy of antimicrobials (i.e., bac-
tericidal or bacteriostatic activity) based on animal
models [26]. In our cohort, the incidence of vancomycin
tolerance was approximately 4%. We did not observe an
association between vancomycin tolerance and increased
mortality although we had small numbers of vancomy-
cin-tolerant isolates in our cohort. In our study, vanco-
mycin MBC was highly correlated with vancomycin
MIC; over 70% of isolates revealed an identical value of
vancomycin MIC and MBC. Based on our findings,
MBC and vancomycin tolerance is likely to be of limited
value as a predictor of outcomes in MRSA bacteremia
patients treated with vancomycin.
Our study demonstrated that patient factors, such as
patient’s age, co-morbidities, presence of devices, and
ICU admission ≤ 48 hours after first positive blood cul-
ture are predictive of short-term mortality associated
with MRSA bacteremia, similar to what has been noted
by others [27-29]. This suggests that earlier identifica-
tion of high risk patients, and timely management in the
early stage of illness are important in reducing mortality
in MRSA bacteremia.
Our study has several limitations. It occurred in a sin-
gle, tertiary care center, and may not be generalizable to
other hospitals. The extent of diseases associated with
MRSA bacteremia was not fully evaluated in this study,
especially the presence of endocarditis, since not all
patients with MRSA bacteremia underwent further eva-
luation such as transesophageal echocardiogram [30]. In
this cohort, transesophageal echocardiogram was only
performed for only 17.2% (18/163) of patients. Clinical
information at the time of diagnosis, such as, intensive
care unit admission 48 hours or less at the time of diag-
nosis, active malignancy, and cirrhosis was used as a
predictor of the severity of the illness. We were unable
to collect information to calculate Acute Physiology and
Chronic Health Evaluation II score and Charlson
comorbidity index which may be more appropriate for a
predictor of the severity of illness. Although vancomycin
trough level was are generally obtained before the fourth
dose at our institution, 7.4% of patients in our study did
not have a trough level drawn, and the timing of when
vancomycin trough level were obtained for the remain-
der of other cohort was not standardized. Persistent bac-
teremia (i.e., > 7 days bacteremia) [31] occurred in only
one patient in our cohort; therefore, we were unable to
assess the relationship between vancomycin MIC and
duration of bacteremia. Despite having prospective data
on over 163 patients and an overall mortality rate of
21.5%, our study is not powered to detect small differ-
ences in mortality due to infection from MRSA isolates
with either low or high vancomycin MICs. While our
data did not support a direct relationship vancomycin
MIC and mortality in patients with MRSA bacteremia,
this finding may not apply to other invasive MRSA
infection, especially those involving other organs (e.g.,
central nervous system, bone, and eye) in which the
physiologically achievable vancomycin concentration is
lower than in blood. Due to the low incidence of VISA
bacteremia in our cohort, we were unable to assess the
impact of VISA on mortality.
Conclusion
We found that reduced vancomycin susceptibility and
vancomycin tolerance were not associated with signifi-
cant differences in 28-day mortality among a cohort of
patients with MRSA bacteremia. Other patient risk fac-
tors are likely associated with unfavorable clinical out-
come. Even with the rising incidence of infections due
to MRSA strains with reduced vancomycin MIC, vanco-
mycin is still the first-line agent for treating MRSA bac-
teremia. Our data suggest that for bacteremia due to
MRSA with a vancomycin MIC of 2 μg/mL, vancomycin
may still remain a viable treatment option.
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